An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer

Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)

This observational study will evaluate the efficacy and safety of different capecitabine based chemotherapies, alone or in combination with other therapies, as first line treatment of metastatic colorectal cancer in participants during everyday clinical practice.

Inclusion Criteria:

• Participants with newly diagnosed mCRC who have started first-line capecitabine-based chemotherapy in accordance with the current Hungarian label

Exclusion Criteria:

• History of serious or unexpected reaction to fluoropyrimidine therapy
• Hypersensitivity to the active ingredient of Xeloda or to any of the excipients of the product, or to fluorouracil
• Known dihydropyrimidine dehydrogenase deficiency
• Pregnancy or lactation
• Inadequate bone marrow, hepatic or renal function
• Treatment with sorivudine or its chemical analogues (for example, brivudine)
• If any contraindication for any drug used in the combination treatment schedules is present, the drug in question cannot be used